Healthcare Industry News: Merck
News Release - January 14, 2014
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery DiseaseCAMBRIDGE, Mass. & TEL AVIV, Israel--(Healthcare Sales & Marketing Network)--ARIAD Pharmaceuticals, Inc. (ARIA) and Medinol, Ltd. today announced the initiation of two registration trials of Medinol’s NIRsupremeTM Ridaforolimus-Eluting Coronary Stent System incorporating ARIAD’s mTOR inhibitor, ridaforolimus. The two NIRsupreme clinical trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and Canada and will enroll approximately 2,200 patients with coronary artery disease. ARIAD licensed ridaforolimus to Medinol for use in drug-eluting stents in 2005. Drug-eluting stents (DES) are now implanted in over 500,000 patients yearly in the United States.
The commencement of patient enrollment in Medinol’s clinical trials, along with the submission of an investigational device exemption with the U.S. Food and Drug Administration, triggers milestone payments to ARIAD of $3.75 million, with the potential for additional regulatory, clinical and sales milestones, as well as royalties on product sales.
The BIONICS trial aims to show that the NIRsupreme stent is comparable (non-inferior) to a comparator drug-eluting stent with the primary endpoint of coronary target lesion failure (a composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization) at 12 months. This trial is expected to enroll approximately 1,900 patients.
The NIREUS trial aims to demonstrate angiographic non-inferiority of the NIRsupreme stent to a comparator stent and has a primary endpoint of late loss in lumen diameter within the stent determined by coronary angiography at six months. This trial is expected to enroll approximately 300 patients.
“We are pleased to have one of the most innovative and successful medical device companies advance the development and potential commercialization of drug-delivery stents incorporating ridaforolimus,” said Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “We believe that Medinol has developed a unique elastomeric formulation and stent platform, and we are delighted by the value created through this successful long-term collaboration with a true innovator.”
ARIAD entered into a non-exclusive agreement with Medinol to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent reblockage of injured vessels following stent-assisted angioplasty. ARIAD is eligible to receive additional regulatory, clinical and commercial milestones of up to $34.75 million, if two products are developed, plus royalties on worldwide product sales. ARIAD is responsible for supplying ridaforolimus to Medinol, and Medinol is responsible for the development and commercialization of the medical devices delivering ridaforolimus. These rights are separate from those licensed to Merck for use of ridaforolimus in oncology.
“We are proud and excited to initiate the BIONICS and NIREUS clinical trials,” said Yoram Richter, Ph.D., chief scientific officer at Medinol. “NIRsupreme, the first ever elastomer-based DES, is the outcome of meticulous research towards uniform, controlled drug release. We believe that this is the evolution that interventional cardiologists have been waiting for. Medinol is privileged to cooperate with ARIAD, a leading drug developer, and has high expectations for this partnership,” Dr. Richter concluded.
Ridaforolimus is an investigational targeted and potent small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN, known to be important to malignancy. Ridaforolimus also blocks the proliferation and migration of vascular smooth muscle cells, the primary cause of narrowing and reblockage of injured arteries, and is an analog of sirolimus, another mTOR inhibitor that has been approved for use on drug-eluting stents. Ridaforolimus is currently licensed to Medinol for medical devices and to Merck for oncology.
Medinol, Ltd. is a global leader in the field of stents and stenting systems. Medinol has developed the QualitySurfaceTM technology, a unique approach to stent manufacturing and coating. Its new-generation stents, the NIRsupremeTM drug-eluting stent and NIRxcellTM bare-metal stent, reflect the company's commitment to continuous innovation, unique product design and uncompromising quality products. NIRsupremeTM, the first ever elastomer-based drug-eluting stent (eDESTM), provides an elastomeric coating to ensure perfect surface integrity combined with uniform drug-release. Medinol, founded in 1992, is privately held and headquartered in Tel Aviv, Israel. Additional information about Medinol can be found on the web at http://www.medinol.com.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
This press release contains “forward-looking statements” which are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the availability and adequacy of supply of NIRsupreme Ridaforolimus-Eluting coronary stents for conducting the clinical trials; the pace of enrollment of subjects in the clinical trials and time to completion of the studies; the results obtained from the studies, the review and acceptance of such results by appropriate regulatory agencies, and the decisions made by regulatory agencies based on such results; the achievement and timing of future milestone-triggering events and the clinical and commercial success of the NIRsupreme Ridaforolimus-Eluting coronary stents. These factors, risks and uncertainties also include, but are not limited to: preclinical data and early-stage clinical data for ARIAD’s product candidates that may not be replicated in later-stage clinical studies; the costs associated with ARIAD’s research, development, manufacturing, commercial and other activities; the conduct, timing and results of pre-clinical and clinical studies of ARIAD’s product candidates; the adequacy of ARIAD’s capital resources and the availability of additional funding; and other factors detailed in the ARIAD's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. After the date of this document, ARIAD does not intend to update any of the forward-looking statements to conform to actual results or to changes in ARIAD’s expectations, except as required by law.
Source: ARIAD Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.